Searched for
ARV DRUGS
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Adequate stock of antiretroviral drugs for 95% 'People Living with HIV' in India: SourcesThere is no reported stock out for any antiretroviral (ARV) drugs at the state level and fresh supply orders for procurement of the next lo...
- Pharma companies set to supply ARVs for ‘treatment’Though there is no formal cure discovered to treat the virus, the treatment protocol established in China and confirmation by physicians in...
- Mylan gets approval to launch HIV drug in India, says it will be priced “lower” than othersAround 21 lakh people are estimated to be living with HIV in India but only 14 lakh are known cases, according to the health ministry.
- India calls for flexibilities in IPR to combat AIDSJP Nadda said India will need to "front load" its investments substantially to almost double the number of people on ARV treatment in less ...
- Government exempts AIDS drugs from customs dutyThe exemption will benefit Anti-Retroviral Drugs (ARV Drugs) -- Adult First Line, Adult Second Line and Paediatric Drugs.
- India not promoting Tenofovir, an HIV treatment drug that can also prevent the diseaseThe recommendation opens up a new debate on the use of ARVs as a preventive drug and how it will be perceived among those who engage in uns...
- Ranbaxy reassures South Africans local drugs are safeRanbaxy has assured the public that drugs manufactured locally are safe days after the Indian firm paid a fine of $500 million in the US.
- CCI rules out case against Gilead SciencesCCI has rejected a complaint against Gilead Sciences Inc that alleged the US-based pharmaceutical company of abusing its dominant position.
- Cipla to develop formulation for HIV +ve children with DNDiCipla will work to produce an appropriate 4-in-1 combination sachet product for easy mixing into food or liquids such as water, juice, or b...
- Ranbaxy arm bags Rs 605 cr anti-HIV drug order in South AfricaThe 913.5 million rand order bagged by Sonke is a part of a 4.28 billion rand national anti-retroviral tender floated by the South African ...
- Hind Antibiotics to make new HIV drugsPublic sector pharmaceutical company Hindustan Antibiotics will start production of cephalsporins with plans to revive production of new an...
- Ranbaxy, Cipla among Indian cos in race for $200 mn drug dealRanbaxy Laboratories, Cipla and Aurobindo Pharmaceuticals are submitting bids for the $200 mn South African govt tender to supply anti-HIV ...
- Patent on AIDS drugs could hike costs: GovtGovernment on Friday said granting of patents to HIV/AIDS drugs might increase cost of the medicines and create problems for patients, alth...
- J&J gets patent for ARV drug EtravirineUS major Johnson and Johnson (J&J) has been granted a patent for its anti retroviral drug (ARV) Etravirine in India-the second anti-ARV dru...
- Ranbaxy gets USFDA nod to market two ARV drugsRanbaxy Laboratories has received US Food and Drug Administration’s (USFDA) approval to manufacture and market two paediatric anti-retrovir...
- Ranbaxy clocks $100 mn sales a yearAfrica has been a silent money spinner for India's drug maker Ranbaxy generating about $100 mn every year.
- JB Chem ties up with US co for anti-HIV drugJB Chemicals & Pharmaceuticals Ltd on Friday said it has signed a non-exclusive license agreement with US-based Gilead Sciences Inc to manu...
- Ranbaxy gets approval to produce, sell anti-AIDS drugCountry's largest drug maker, Ranbaxy Laboratories Limited (RLL) on Monday said it had received approval to manufacture and market anti-AID...
Load More
